The pipeline for dry eye disease drugs is beginning to heat up ... Novartis paid Takeda $3.4 billion for its FDA-approved dry eye drug Xiidra during the Japanese pharma’s merger with Shire ...
Shire’s potential blockbuster Xiidra (lifitegrast ... in phase 2 and has glaucoma and retinitis pigmentosa drugs in preclinical development. Orsnkov said: “As Shire’s first FDA-approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback